Inactive Instrument

Highlights VectivBio Holding AG

Equities

VECT

CH1109007893

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ironwood Pharmaceuticals, VectivBio Say Tender Offer for VectivBio Shares Completed	23-06-29	MT
Ironwood Pharmaceuticals, Inc. completed the acquisition of VectivBio Holding AG from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others.	23-06-28	CI
VectivBio Says Takeover by Ironwood Pharmaceuticals Approved at Extraordinary Shareholder Meeting	23-06-26	MT
Ironwood Pharmaceuticals Tender Offer for VectivBio Clears Antitrust Waiting Period	23-06-16	MT
VectivBio Holding Ag Approves Amendments to the Articles of Association	23-06-02	CI
Ironwood Pharmaceuticals to Buy VectivBio for $1 Billion, Enhancing Gastrointestinal Portfolio	23-05-22	MT
Ironwood Pharmaceuticals to Acquire Switzerland-Based VectivBio for About $1 Billion	23-05-22	MT
Ironwood Pharma To Acquire VectivBio For $1.15 Billion	23-05-22	RE
Ironwood bulks up on digestive therapies with $1.15 bln VectivBio buy	23-05-22	RE
Ironwood Pharma to acquire Swiss-based VectivBio in $1 bln deal	23-05-22	RE
Ironwood Pharmaceuticals, Inc. entered into definitive agreement to acquire VectivBio Holding AG for $1 billion.	23-05-21	CI
VectivBio Reports Narrower Loss for Full-Year 2022	23-04-19	MT
VectivBio Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Vectivbio Holding Ag and Asahi Kasei Pharma Corporation Announce the Start of A Phase 1 Study of Apraglutide in Japan	23-03-13	CI
VectivBio Announces Results of Extraordinary General Meeting-Wouter Joustra Elected to the Board of Directors	22-12-12	AQ
VectivBio Announces Results of Extraordinary General Meeting	22-12-09	GL
VectivBio Announces Results of Extraordinary General Meeting	22-12-09	AQ
Vectivbio Holding AG Appoints Wouter Joustra as Member of the Board of Directors	22-12-09	CI
VectivBio Holding AG Announces Completion of Enrollment for Colon-In-Continuity Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure	22-11-03	CI
VectivBio Holding AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VectivBio Holding AG

Equities

VECT

CH1109007893

Highlights

Filters